We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




ML Algorithm Accurately Identifies Cancer-Specific Structural in Long-Read DNA Sequencing Data

By LabMedica International staff writers
Posted on 31 May 2025

Long-read sequencing technologies are designed to analyze long, continuous stretches of DNA, offering significant potential to enhance researchers' abilities to detect complex genetic changes in cancer genomes. More...

However, due to the intricate structure of cancer genomes, standard analysis tools, including those developed specifically for long-read sequencing data, often fall short. This can lead to false positives and unreliable data interpretations, ultimately undermining our understanding of how tumors evolve, respond to treatments, and affect patient diagnosis and management. To overcome this issue, researchers have developed a machine learning algorithm capable of identifying cancer-specific structural variations and copy number changes in long-read DNA sequencing data.

The algorithm, named SAVANA, was developed by researchers at the European Bioinformatics Institute (EMBL-EBI, Barcelona, Spain) and Genomics England's R&D laboratory (London, UK), in collaboration with clinical partners. SAVANA utilizes machine learning techniques to precisely identify structural variants—such as insertions, deletions, duplications, and rearrangements—along with the resulting copy number changes in cancer genomes using long-read sequencing data. Because cancer genomes are complex, traditional analysis tools often generate false positives, leading to inaccurate clinical interpretations of tumor biology. SAVANA significantly reduces these errors. The algorithm, described in Nature Methods, was tested on 99 human tumor samples, and its rapid processing and strong error-correction capabilities make it ideal for clinical applications. Recently, the method was applied to study osteosarcoma, a rare and aggressive bone cancer, where it helped uncover novel genomic rearrangements, shedding light on the mechanisms behind osteosarcoma's progression.

The team also compared SAVANA’s results from long-read data with data generated using Illumina sequencing, applying the standard whole-genome sequencing pipeline used in clinical settings. The results were highly consistent across both technologies, showing that SAVANA matches current clinical standards while revealing additional cancer-related alterations. SAVANA provides fast and reliable genomic analysis, which enhances the interpretation of clinical samples and improves cancer diagnosis and treatment strategies. This initiative represents the first global effort to incorporate whole-genome sequencing into routine clinical care. By integrating genomics into everyday clinical practice, the goal is to improve diagnostic precision and support personalized treatment plans for cancer patients. However, to achieve the full benefits of clinical genomics, accurate genomic data interpretation is essential, and this depends on specialized analytical tools. As part of its efforts to explore the clinical potential of long-read sequencing technology for faster and earlier cancer diagnosis, Genomics England has incorporated SAVANA into its research.

“Using SAVANA will ensure clinicians receive accurate and reliable genomic data, enabling them to confidently integrate advanced genomic sequencing methods such as long-read sequencing into routine patient care,” said Greg Elgar, Director of Sequencing R&D at Genomics England.

Related Links:
EMBL-EBI
Genomics England


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Enterovirus Test
Quanty Enterovirus System
New
Multilevel Whole Blood Calibrator Set
6PLUS1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Molecular Diagnostics

view channel
Image: A family of molecules could help diagnose and treat breast cancer (Photo courtesy of Shutterstock)

Molecular Biomarkers Pave Way for New Tests to Diagnose and Predict Breast Cancer

Despite playing essential roles in tissue development and immune protection, the contribution of proteoglycans in cancer remains poorly understood. Some proteoglycans appear to shield the body from cancer,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: T cell immunity could be a marker for early Parkinson’s treatment (Photo courtesy of Shutterstock)

T Cells in Blood Can Detect Parkinson's Years Before Diagnosis

Diagnosing Parkinson’s disease before the appearance of motor symptoms remains one of neurology’s most significant challenges. Patients can go years—even decades—without a diagnosis, as subtle early indicators... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.